Trials / Completed
CompletedNCT03471130
Definitive QT Study With MT-8554
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of MT-8554 at Two Dose Levels, MT-8554 Low Dose and MT-8554 High Dose, on the QT/QTc Interval in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- Sponsor
- Tanabe Pharma America, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the change of the QT interval corrected for heart rate (HR) using the Fridericia formula (QTcF) from Baseline in healthy adult subjects
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT-8554 Low dose | Oral, 7 days |
| DRUG | MT-8554 High dose | Oral, 7 days |
| DRUG | Placebo | Oral, 7 days |
Timeline
- Start date
- 2018-04-23
- Primary completion
- 2018-10-19
- Completion
- 2018-10-19
- First posted
- 2018-03-20
- Last updated
- 2025-12-17
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03471130. Inclusion in this directory is not an endorsement.